Zejula
GSK, Ivy Brain Tumor Center to Begin Phase III Trial of Zejula in MGMT Unmethylated Glioblastoma
The Phase III trial was initiated after researchers reported promising results from a Phase 0/II trial of Zejula in this setting.
GSK, Ideaya Studying GSK101 Plus Zejula in Homologous Recombination Repair-Deficient Solid Cancers
The firms jointly developed the pol theta helicase inhibitor, which they are testing with a PARP inhibitor in a GSK-sponsored Phase I/II trial.